Inventor · disambiguated record
Gregory Motz
Also filed as: MOTZ GREGORY
6 granted patents·18 pending applications·1 citations·filing 2016–2025
70Inventor score
Top patents by PatentIndex Score
24 records- 0186US12415776B2Lipid nanoparticle compositions for delivering circular polynucleotidesORNA THERAPEUTICS INC·Filed 2023·Granted Sep 16, 2025·0 cites·28 claims
- 0286US12384741B2Lipid nanoparticle compositions for delivering circular polynucleotidesORNA THERAPEUTICS INC·Filed 2023·Granted Aug 12, 2025·0 cites·28 claims
- 0386US12180138B2Lipid nanoparticle compositions for delivering circular polynucleotidesORNA THERAPEUTICS INC·Filed 2023·Granted Dec 31, 2024·0 cites·28 claims
- 0486US12077485B2Lipid nanoparticle compositions for delivering circular polynucleotidesORNA THERAPEUTICS INC·Filed 2023·Granted Sep 3, 2024·0 cites·28 claims
- 0575US11999802B2Compositions and methods for selective protein degradationNOVARTIS AG·Filed 2018·Granted Jun 4, 2024·1 cites·33 claims
- 0671US2024384007A1Compositions and methods for selective protein degradationNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0767US2023139800A1Car t cell therapies with enhanced efficacyNOVARTIS AG·Filed 2022·Application pending·0 cites
- 0866US2024376442A1Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereofSOTIO BIOTECH INC·Filed 2024·Application pending·0 cites
- 0962US2025290042A1Genetically modified cells for enhanced immune evasion in allogeneic cellular therapiesBLUEROCK THERAPEUTICS LP·Filed 2025·Application pending·0 cites
- 1062US2025268828A1Lipid Nanoparticle Compositions for Delivering Circular PolynucleotidesORNA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1159US12077785B2Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereofSOTIO BIOTECH INC·Filed 2019·Granted Sep 3, 2024·0 cites·23 claims
- 1259US2025283073A1Circular RNA Compositions and MethodsORNA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1357US2025243462A1Genetically modified cells for enhanced immune evasion in allogeneic cellular therapiesBLUEROCK THERAPEUTICS LP·Filed 2025·Application pending·0 cites
- 1455US2025382621A1Immune effector cell therapies with enhanced efficacyNOVARTIS AG·Filed 2025·Application pending·0 cites
- 1550US2024390495A1Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereofSOTIO BIOTECH INC·Filed 2022·Application pending·0 cites
- 1648US2021340219A1Chimeric receptor polypeptides in combination with trans metabolism molecules modulating intracellular lactate concentrations and therapeutic uses thereofSOTIO LLC·Filed 2019·Application pending·0 cites
- 1747US2022054545A1ANTI-GPC3 CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOFSOTIO LLC·Filed 2019·Application pending·0 cites
- 1847US2021261646A1Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereofSOTIO LLC·Filed 2019·Application pending·0 cites
- 1945US2019000880A1Immune effector cell therapies with enhanced efficacyMOTZ GREGORY·Filed 2016·Application pending·0 cites
- 2043US2018258149A1Car t cell therapies with enhanced efficacyMOTZ GREGORY·Filed 2016·Application pending·0 cites
- 2138US2020181226A1Antibody-coupled t cell receptor constructs and therapeutic uses thereofUNUM THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2237US2023071283A1Compositions and methods for selective protein expressionGOLOSOV ANDREI·Filed 2017·Application pending·0 cites
- 2336US2019284298A1Use of antibody-coupled t cell receptor (actr) with multiple anti-cancer antibodies in cancer treatmentUNUM THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2435US2019298715A1Immune effector cell therapies with enhanced efficacyMOTZ GREGORY·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →